Clinical Commissioning Policies
This page lists the Clinical Commissioning Policies – known locally as Lavender Statements – that have been adopted by OCCG’s Board. NHS organisations caring for Oxfordshire patients must take account of these statements when considering treatment or referral to other specialists.
301 Biologic Drugs for the Management of Axial Spondyloarthritis
302 Biologic Drugs for the Management of Crohn's Disease
303 Treatment of Chalazia
304 Anti VEGFs for the Management of Sight-threatening Rare Eye Conditions
305 Management of Earwax
306 Immunotherapy for Allergic Rhinoconjunctivitis
307 Sodium Oxybate
308 Application of the use of ADL to IFR
309 Posterior tibial nerve stimulation in paediatric patients
310 Use of biological and immunomodulatory therapies in moderate Rheumatoid Arthritis
311 Prostate Specific Antigen Testing
312 Surgical Removal of Kidney Stones
313 Surveillance Colonoscopy Post-Polypectomy and Post Colorectal Cancer Resection
314 Colonoscopy in the Management of Hereditary Colorectal Cancer
316 Treatment of Voiding Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)